Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology
Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs. Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers.
"Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval," said Pablo Jordan, CEO and co-founder of Dreampath Diagnostics. "Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We're proud to partner with Summit to help us scale our impact and reach more patients around the world."
Dreampath's integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company's technology is tailored to specific stages of the pathology process and works with Dreampath's proprietary software and consumables. This closed-loop system helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden. Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples.
Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by strong demand for its platform across the U.S., EMEA and other global markets. Dreampath's customers include many of the world's foremost cancer centers, as well as some of the largest and most sophisticated commercial laboratories in operation today.
"Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven't meaningfully evolved in decades," said Thomas Tarnowski, Managing Director at Summit Partners. "Dreampath's platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale."
"We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics," added Jono Pagden, Principal at Summit Partners. "In our view, the company's first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We're proud to be their first institutional partner and excited to support the team in scaling their impact globally."
Both Thomas Tarnowski and Jono Pagden have joined the Dreampath Board of Directors.
Dreampath is headquartered in Strasbourg, France with a U.S. commercial office in New York.
Financial terms of the transaction were not disclosed.
About Dreampath Diagnostics
Dreampath Diagnostics is a global leader of digital sample management systems for anatomical pathology laboratories. The company's patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance. Dreampath's systems are used in leading labs and institutions across nearly 40 countries. For more information, please visit www.dreampathdx.net.
About Summit Partners
Summit Partners is a leading growth-focused investment firm. Summit invests across growth sectors of the economy and, since the firm's founding in 1984, has invested in more than 550 companies in technology, healthcare and other growth industries. These companies have completed more than 175 public equity offerings, and more than 250 have been acquired through strategic mergers and sales. Notable investments in healthcare and life sciences include Advance Medical, CluePoints, Healthline Media, LifeStance Health, VaxCare and Viroclinics. Summit maintains offices in North America and Europe and seeks to invest in category-leading, profitable growth companies worldwide. For more information, please visit www.summitpartners.com or follow on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250711981841/en/
Contacts
Media Contact:Susan Barrsbarr@summitpartners.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
ECS Cloud-Based Mission Partner Environment, Blue Dawn, Officially Launches on Department of Defense Tradewinds Solutions Marketplace
Leveraging commercially available technology, Blue Dawn provides scalable infrastructure for mission partner collaboration in multiple mission sets and environments FAIRFAX, Va, August 13, 2025--(BUSINESS WIRE)--ECS, a provider of advanced technology solutions in data and AI, cybersecurity, and enterprise transformation, and an ASGN (NYSE: ASGN) brand, announced today that Blue Dawn, the company's cloud-based mission partner environment (MPE) infrastructure solution, has been officially designated "awardable" on the Department of Defense (DoD) Chief Digital and Artificial Intelligence Office's (CDAO) Tradewinds Solutions Marketplace. The Tradewinds Solutions Marketplace is the premier offering of Tradewinds, the DoD's suite of tools and services designed to accelerate the procurement and adoption of Artificial Intelligence (AI)/Machine Learning (ML), data, and analytics capabilities. With this awardable status, Blue Dawn is now available as a contract-ready solution, streamlining acquisition for government customers seeking a cloud-based infrastructure that delivers mission outcomes, is IL5 and IL6 compliant, and enables secure collaboration, data interoperability, and AI development across high-security environments using a streamlined commercial delivery model. In addition to AI development, Blue Dawn enables secure coordination over a range of mission areas, from operational decision making and foreign aid, to logistics and training, to the delivery of military equipment and maintenance support, quickly and at scale. "This milestone underscores ECS' dedication to delivering a secure platform, backed by the most advanced commercial technologies, that empowers collaboration, accelerates mission execution, and meets the evolving digital demands of the DoD," said John Heneghan, president of ECS. "Blue Dawn represents our commitment to innovation, interoperability, and future-ready solutions for our nation's most critical defense priorities." ECS' video submission for the assessment, "Blue Dawn Mission Partner Collaboration (IL5 and IL6)," accessible only by government customers on the Tradewinds Solutions Marketplace, presents several actual use cases including a case in which ECS enabled mission partner collaboration between several allied nations during a global crisis. Government customers interested in viewing the video submission can create a Tradewinds Solutions Marketplace account at About ECS ECS, a key segment of ASGN Incorporated, provides advanced technology solutions that enable fast and efficient decision making and deliver mission outcomes. ECS' leading-edge AI, cybersecurity, and open data management solutions boost collaboration, innovation, and worker productivity, improve employee and customer experiences, and protect critical agency data and assets. For more information, visit About ASGN Incorporated ASGN Incorporated (NYSE: ASGN) is a leading provider of IT services and solutions across the commercial and government sectors. ASGN helps corporate enterprises and government organizations develop, implement, and operate critical IT and business solutions through its integrated offerings. For more information, please visit About the Tradewinds Solutions Marketplace The Tradewinds Solutions Marketplace is a digital repository of post-competition, readily awardable pitch videos that address the Department of Defense's (DoD) most significant challenges in the Artificial Intelligence/Machine Learning (AI/ML), data, and analytics space. All awardable solutions have been assessed through complex scoring rubrics and competitive procedures and are available to Government customers with a Marketplace account. Government customers can create an account at Tradewinds is housed in the DoD's Chief Digital Artificial Intelligence Office. For more information or media requests, contact: Success@ Safe Harbor Certain statements made in this news release are "forward-looking statements" within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and involve a high degree of risk and uncertainty. Forward-looking statements include statements regarding our anticipated financial and operating performance. All statements in this news release, other than those setting forth strictly historical information, are forward-looking statements. Forward-looking statements are not guarantees of future performance and actual results might differ materially. For a full list of risks and discussion of forward-looking statements, please see our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 24, 2025. We specifically disclaim any intention or duty to update any forward-looking statements contained in this news release. View source version on Contacts Shab Nassirpour, ECS Vice President of Marketing and Communications(703) Kimberly Esterkin, Vice President, Investor Relations,
Yahoo
8 minutes ago
- Yahoo
HeartFlow IPO success reflects market embrace of AI in medtech industry
HeartFlow's $364m initial public offering (IPO) signals market validation for the use of artificial intelligence (AI) in a company's product portfolio, an expert says. Roundly exceeding its $300m expectations for the IPO, the Bain Capital-backed AI-based coronary artery disease (CAD) platform developer debuted with a a $2.2bn valuation on the Nasdaq on 8 August. HeartFlow's current products are HeartFlow Plaque analysis, which aims to provide clinicians with the ability to more accurately assess patients with arterial plaque buildup (atherosclerosis), and HeartFlow FFRCT analyses CT angiogram (CCTA). Typically used alongside Plaque Analysis, FFRCT creates detailed 3D models of the arteries to assess the impact of blockages on blood flow. Plaque Analysis received US Food and Drug Administration (FDA) clearance in 2022 and is claimed to be the only AI-based plaque quantification tool currently cleared by the agency. FFRCT received FDA clearance in 2014. To reach the IPO milestone, HeartFlow maintained a focus on testing its product offerings alongside physicians, generating real world evidence, taking on feedback and refining as needed, and ensuring they were truly ready to scale. HeartFlow also navigated the structural barriers of getting its product to market; again, real-world evidence – with over 3,000 peer-reviewed papers demonstrating its products' efficacy – spurred the company's commercialisation efforts. Medtech industry veteran, Brent Ness, CEO of Aclarion, who served as HeartFlow's chief commercial officer from 2014 to 2015, told Medical Device Network that HeartFlow's work on the underlying economic factors around its product, including working on contractual relationships with imaging centres to get them on board with the product, pre-reimbursement, have proven a key part of its success. 'Between FDA clearance and reimbursement, lots of technologies can't make it through that journey because there's no reimbursement, and therefore there's no adoption, and they run out of cash,' Ness explained. 'Part of the structural barrier stage of development involves getting the provider economics right and that market access work that needs to take place between the early payors and the key opinion leaders (KOL) advocating for the product. But payors aren't going to turn it on just because a KOL says so. 'This is why the shining jewel in HeartFlow's history has been their absolute commitment to leading with evidence.' AI's recognition in healthcare and its future According to Ness, the success of HeartFlow's IPO reflects the market validation of the overall rationale for using AI in imaging and the deployment of software-as-a-service (SaaS) based products as the 'raw material' underpinning the technology's ability to provide clinically actionable information and improve patient outcomes. Ness said this model is 'here to stay', having been 'completely validated by the market, which has recognised of its value, which obviously translates into revenue, and speaks to the long term success and viability of HeartFlow and the significant potential for other AI-based SaaS imaging developers.' To learn from HeartFlow's success, Ness views a critical role for SaaS-based AI software providers as being to try and shorten the timeframe between regulatory approval and reimbursement. 'The faster that new and novel technologies using AI can move through that Death Valley, the better it's going to be for patients, and the more money we're going to save as a collective society,' Ness said. 'The 'muscle' of these AI tools is proving to be valuable. It's got to be safe, and it's got to make sense economically, but we've got to figure out how to shorten that part of the journey.' "HeartFlow IPO success reflects market embrace of AI in medtech industry" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Biggest IKEA retailer names veteran Juvencio Maeztu CEO as Brodin steps down
By Helen Reid LONDON (Reuters) -The world's biggest retailer of IKEA furniture said on Wednesday CEO Jesper Brodin was stepping down after eight years, to be succeeded by Spaniard Juvencio Maeztu, the first non-Swede to lead the group. Maeztu takes the top job at Ingka Group as the Swedish retailer grapples with U.S. tariffs, wars and geopolitical tensions that risk disrupting its operations spanning 31 countries from Europe to China, India and the United States. Brodin, CEO since 2017, said his decision to step down was not easy, but that it was the right time to do so. Maeztu is to start in the new role by November 5, with Brodin staying at the company until the end of February to ease the transition. Deputy CEO and chief financial officer since 2018, Maeztu, 57, started at IKEA in 2001 as manager of the Alcorcon store in Madrid, later managing the Wembley store in London, before a six-year stint as CEO of IKEA India. "We've been riding through quite some storms together - pandemic, geopolitical issues, war, etcetera," Brodin, 56, told Reuters. "So in a way I feel proud of the things we have achieved but also super confident that the IKEA house is in good order and we'll be able to take off for the future with Juvencio." Under Brodin, Ingka Group invested heavily to improve online shopping for IKEA, driving the retailer's online sales up. Ingka also set new emissions reduction targets and reported in January that emissions fell by 30.1% from its 2016 baseline. Brodin said the appointment of Maeztu, who grew up in Cadiz and does not speak Swedish, shows IKEA's global culture works. The incoming CEO is setting off on a "listening tour" of its big blue stores around the world, starting in Asia, as he builds his strategy to grow the company which last year reported weaker net profit and revenue after slashing prices. "I am fully determined to make IKEA grow and to really be relevant for many millions more consumers around the world," Maeztu told Reuters. He has said tariffs make it harder for IKEA to keep prices low. Privately-held Ingka Group will report sales figures in mid-October for its financial year ending August 31. As the biggest franchisee, Ingka sells IKEA products manufactured by brand owner and franchiser Inter IKEA. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
